Oramed Pharmaceuticals Stock Today
| ORMP Stock | USD 2.20 0.05 2.22% |
Performance0 of 100
| Odds Of DistressLess than 44
|
Oramed Pharmaceuticals is selling at 2.20 as of the 31st of January 2025; that is 2.22 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 2.18. Oramed Pharmaceuticals has about a 44 percent probability of financial distress in the next few years of operation and has generated negative returns over the last 90 days. Note, on January 14, 2022, Representative Andrew Garbarino of US Congress acquired under $15k worth of Oramed Pharmaceuticals's common stock.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 21st of April 2006 | Category Healthcare | Classification Health Care |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York. The company has 40.77 M outstanding shares of which 248.15 K shares are now shorted by private and institutional investors with about 3.8 trading days to cover. More on Oramed Pharmaceuticals
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Oramed Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO President | Nadav Esq | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Tel Aviv 60, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsOramed Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Oramed Pharmaceuticals' financial leverage. It provides some insight into what part of Oramed Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Oramed Pharmaceuticals (ORMP) is traded on NASDAQ Exchange in USA. It is located in 1185 Avenue of the Americas, New York, NY, United States, 10036 and employs 8 people. Oramed Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 94.58 M. Oramed Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 40.77 M outstanding shares of which 248.15 K shares are now shorted by private and institutional investors with about 3.8 trading days to cover.
Oramed Pharmaceuticals currently holds about 133.91 M in cash with (10.29 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Oramed Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationOramed Pharmaceuticals owns a total of 40.77 Million outstanding shares. Oramed Pharmaceuticals holds 10.62 pct. of its outstanding shares held by insiders and 17.32 pct. owned by third-party entities. On January 14, 2022, Representative Andrew Garbarino of US Congress acquired under $15k worth of Oramed Pharmaceuticals's common stock.
Check Oramed Ownership Details
Oramed Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Squarepoint Ops Llc | 2024-09-30 | 83.4 K | |
| State Street Corp | 2024-09-30 | 60.1 K | |
| Jane Street Group Llc | 2024-09-30 | 58.3 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 48.8 K | |
| Millennium Management Llc | 2024-09-30 | 46.7 K | |
| Morgan Stanley - Brokerage Accounts | 2024-09-30 | 44.7 K | |
| Lpl Financial Corp | 2024-09-30 | 38.7 K | |
| Ubs Group Ag | 2024-09-30 | 28.2 K | |
| Pnc Financial Services Group Inc | 2024-09-30 | 26.2 K | |
| Bml Capital Management Llc | 2024-09-30 | 2.2 M | |
| Murchinson Ltd. | 2024-09-30 | 1.7 M |
Oramed Pharmaceuticals Historical Income Statement
Oramed Stock Against Markets
Oramed Pharmaceuticals Corporate Executives
Elected by the shareholders, the Oramed Pharmaceuticals' board of directors comprises two types of representatives: Oramed Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oramed. The board's role is to monitor Oramed Pharmaceuticals' management team and ensure that shareholders' interests are well served. Oramed Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oramed Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Avraham Gabay | Treasurer CFO | Profile | |
| Joshua Hexter | COO and VP of Bus. Devel. | Profile |
Additional Tools for Oramed Stock Analysis
When running Oramed Pharmaceuticals' price analysis, check to measure Oramed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oramed Pharmaceuticals is operating at the current time. Most of Oramed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Oramed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oramed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Oramed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.